Psilocybin brain imaging trial for depression
Treatments studied
Part of Mental health clinical trials.
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with major depression (without psychosis) for at least 3 months.
- You do not have bipolar disorder, schizophrenia, or a psychotic disorder (now or in the past).
- You have a responsible adult who can stay with you for 24 hours after each treatment.
- You have a regular doctor or psychiatrist who can provide ongoing care.
- You have not used any psychedelic drugs (like psilocybin, LSD, or ayahuasca) in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
This study tests whether a dose of psilocybin (the active ingredient in magic mushrooms) can help treat depression that hasn't improved with standard antidepressants. Some participants will also take the antidepressant fluoxetine (Prozac) to see if it changes the effects.
This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.
Hear when a new Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.